Combination therapy of surgical tumor resection with implantation of a hydrogel containing camptothecin-loaded poly(lactic-co-glycolic acid) microspheres in a C6 rat glioma model

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 4, 2012, Pages 545-550

  Ozeki, Tetsuya ^a   Kaneko, Daiki ^b   Hashizawa, Kosuke ^b   Imai, Yoshihiro ^b   Tagami, Tatsuaki ^a   Okada, Hiroaki ^b  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Glioma therapy; Poly(lactic co glycolic acid) microsphere; Surgical tumor resection; Sustained release; Thermoreversible gelation polymer

Indexed keywords

CAMPTOTHECIN; INDOCYANINE GREEN; MICROSPHERE; POLYGLACTIN; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE MEASUREMENT; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; GELATION; GLIOMA; HEAT SENSITIVITY; HYDROGEL; IN VIVO STUDY; INJECTION SITE; LONG TERM SURVIVAL; MALE; NONHUMAN; RAT; ROOM TEMPERATURE; SURVIVAL TIME; SUSTAINED DRUG RELEASE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG CARRIERS; DRUG IMPLANTS; GLIOMA; HYDROGELS; LACTIC ACID; MALE; MICROSPHERES; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84859470835     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.545     Document Type: Article

References (23)

1. Lim SK, Llaguno SR, McKay RM, Parada LF. Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Rep, 44, 158-164 (2011).
2. Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M. Current therapeutic paradigms in glioblastoma. Rev. Recent Clin. Trials, 5, 14-27 (2010).
3. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery, 31, 78-82 (1992).
4. Hildebrand J, Dewitte O, Dietrich PY, de Tribolet N. Management of malignant brain tumors. Eur. Neurol., 38, 238-253 (1997).
5. Hoover JM, Chang SM, Parney IF. Clinical trials in brain tumor surgery. Neuroimaging Clin. N. Am., 20, 409-424 (2010).
6. Guerin C, Olivi A, Weingart JD, Lawson HC, Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest. New Drugs, 22, 27-37 (2004).
7. Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J. Biol. Med., 79, 141-152 (2006).
8. Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr. Med. Res. Opin., 24, 3239-3257 (2008).
9. Ozeki T, Hashizawa K, Kaneko D, Imai Y, Okada H. Treatment of rat brain tumors using sustained-release of camptothecin from poly(lactic-co-glycolic acid) microspheres in a thermoreversible hydrogel. Chem. Pharm. Bull., 58, 1142-1147 (2010).
10. Arai T, Joki T, Akiyama M, Agawa M, Mori Y, Yoshioka H, Abe T. Novel drug delivery system using thermoreversible gelation polymer for malignant glioma. J. Neurooncol., 77, 9-15 (2006).
11. Yoshioka H, Mikami M, Mori Y, Tsuchida E. A Synthetic Hydrogel with Thermoreversible Gelation. I. Preparation and Rheological Properties. J. Macromol. Sci., A31, 113-120 (1994).
12. Yoshioka H, Mikami M. Mori Y, Tsuchida E. A Synthetic Hydrogel with Thermoreversible Gelation. Ii. Effect of Added Salts. J. Macromol. Sci., A31, 121-125 (1994).
13. Yoshioka H, Mikami M, Mori Y, Tsuchida E. A synthetic hydrogel with thermoreversible gelation, III: an NMR study of the sol-gel transition. Polym. Adv. Tech., 1994, 122-127 (1994).
14. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Control. Release, 125, 193-209 (2008).
15. Allison SD. Effect of structural relaxation on the preparation and drug release behavior of poly(lactic-co-glycolic)acid microparticle drug delivery systems. J. Pharm. Sci., 97, 2022-2035 (2008).
16. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed., 17, 247-289 (2006).
17. Okada H, Heya T, Ogawa Y, Shimamoto T. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J. Pharmacol. Exp. Ther., 244, 744-750 (1988).
18. Friedman HS, Keir ST, Houghton PJ. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer, 97 (Suppl.), S2359-S2362 (2003).
19. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol., 17, 421-433 (2010).
20. Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J. Neurooncol., 92, 165-175 (2009).
21. Ozeki T, Beppu S, Mizoe T, Takashima Y, Yuasa H, Okada H. Preparation of polymeric submicron particle-containing microparticles using a 4-fluid nozzle spray drier. Pharm. Res., 23, 177-183 (2006).
22. Rostomily RC, Keles GE, Berger MS. Radical surgery in the management of low-grade and high-grade gliomas. Baillieres Clin. Neurol., 5, 345-369 (1996).
23. Nakabayashi H, Sakaguchi M, Katsuyama J, Hakuba A. Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression. J. Neurooncol., 24, 209-217 (1995).